{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:14:09Z","timestamp":1784542449034,"version":"3.55.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T00:00:00Z","timestamp":1643414400000},"content-version":"am","delay-in-days":393,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.therap.2020.05.013","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T14:24:40Z","timestamp":1593181480000},"page":"5-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Calcium channel blocker exposure and psoriasis risk: Pharmacovigilance investigation and literature data"],"prefix":"10.1016","volume":"76","author":[{"given":"Brahim","family":"Azzouz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Laugier-Castellan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Sanchez-Pena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Rouault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukshe","family":"Kanagaratnam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Trenque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.therap.2020.05.013_bib0175","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/jdv.13854","article-title":"A systematic review of worldwide epidemiology of psoriasis","volume":"31","author":"Michalek","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.therap.2020.05.013_bib0180","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu Rev Immunol"},{"issue":"9997","key":"10.1016\/j.therap.2020.05.013_bib0185","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.therap.2020.05.013_bib0190","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.molimm.2014.12.014","article-title":"Genetic and epigenetic basis of psoriasis pathogenesis","volume":"64","author":"Chandra","year":"2015","journal-title":"Mol Immunol"},{"key":"10.1016\/j.therap.2020.05.013_bib0195","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000106419","article-title":"Environmental factors and psoriasis","volume":"35","author":"Dika","year":"2007","journal-title":"Curr Probl Dermatol"},{"issue":"3","key":"10.1016\/j.therap.2020.05.013_bib0200","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/00128071-200001030-00003","article-title":"Drug-induced psoriasis. Recognition and management","volume":"1","author":"Tsankov","year":"2000","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.therap.2020.05.013_bib0205","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3899\/jrheum.090227","article-title":"Psoriasis induced or aggravated by drugs","volume":"83","author":"Rongioletti","year":"2009","journal-title":"J Rheumatol Suppl"},{"issue":"1","key":"10.1016\/j.therap.2020.05.013_bib0210","first-page":"32","article-title":"Drug-provoked psoriasis: is it drug induced or drug aggravated?","volume":"3","author":"Kim","year":"2010","journal-title":"J Clin Aesthetic Dermatol"},{"key":"10.1016\/j.therap.2020.05.013_bib0215","first-page":"87","article-title":"Drug-induced psoriasis: clinical perspectives","volume":"7","author":"Balak","year":"2017","journal-title":"Psoriasis (Auckl)"},{"key":"10.1016\/j.therap.2020.05.013_bib0220","series-title":"StatPearls [Internet]","article-title":"Calcium channel blockers","author":"McKeever","year":"2020"},{"issue":"5","key":"10.1016\/j.therap.2020.05.013_bib0225","first-page":"6","article-title":"The spectrum of cutaneous reactions associated with calcium antagonists: A review of the literature and the possible etiopathogenic mechanisms","volume":"9","author":"Ioulios","year":"2003","journal-title":"Dermatol Online J"},{"issue":"6","key":"10.1016\/j.therap.2020.05.013_bib0230","doi-asserted-by":"crossref","first-page":"536","DOI":"10.2340\/0001555566536538","article-title":"Diltiazem-associated exfoliative dermatitis in a patient with psoriasis","volume":"66","author":"Lavrijsen","year":"1986","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"10.1016\/j.therap.2020.05.013_bib0235","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1001\/archinte.1989.00390040057011","article-title":"Cutaneous adverse reactions associated with calcium channel blockers","volume":"149","author":"Stern","year":"1989","journal-title":"Arch Intern Med"},{"issue":"5","key":"10.1016\/j.therap.2020.05.013_bib0240","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1346-8138.1993.tb01392.x","article-title":"Cutaneous reactions induced by calcium channel blocker: high frequency of psoriasiform eruptions","volume":"20","author":"Kitamura","year":"1993","journal-title":"J Dermatol"},{"issue":"5","key":"10.1016\/j.therap.2020.05.013_bib0245","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/000155501317140061","article-title":"Calcium channel blockers intake and psoriasis: a case-control study","volume":"81","author":"Cohen","year":"2001","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"10.1016\/j.therap.2020.05.013_bib0250","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/j.1365-2133.2008.08563.x","article-title":"Association between beta-blockers, other antihypertensive drugs and psoriasis: population-based case-control study","volume":"158","author":"Brauchli","year":"2008","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.therap.2020.05.013_bib0255","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/jamadermatol.2013.9957","article-title":"Hypertension, antihypertensive medication use, and risk of psoriasis","volume":"150","author":"Wu","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.therap.2020.05.013_bib0260","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf"},{"issue":"2","key":"10.1016\/j.therap.2020.05.013_bib0265","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.therap.2016.02.010","article-title":"Causality assessment in pharmacovigilance: the French method and its successive updates","volume":"71","author":"Miremont-Salam\u00e9","year":"2016","journal-title":"Therapie"},{"issue":"6","key":"10.1016\/j.therap.2020.05.013_bib0270","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.therap.2019.09.004","article-title":"Pharmacovigilance\u00a0\u2013\u00a0The next chapter","volume":"74","author":"Moore","year":"2019","journal-title":"Therapies"},{"issue":"2","key":"10.1016\/j.therap.2020.05.013_bib0275","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.therap.2018.08.001","article-title":"What is pharmacoepidemiology? Definition, methods, interest and clinical applications","volume":"74","author":"Montastruc","year":"2019","journal-title":"Therapies"},{"issue":"4","key":"10.1016\/j.therap.2020.05.013_bib0280","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1469-1809.1955.tb01348.x","article-title":"On estimating the relation between blood group and disease","volume":"19","author":"Woolf","year":"1955","journal-title":"Ann Hum Genet"},{"issue":"2","key":"10.1016\/j.therap.2020.05.013_bib0285","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/JCP.0b013e31819a4b7c","article-title":"Lithium, antipsychotics, and risk of psoriasis","volume":"29","author":"Brauchli","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.therap.2020.05.013_bib0290","volume":"Vol. 1","author":"Breslow","year":"1980"},{"issue":"4","key":"10.1016\/j.therap.2020.05.013_bib0295","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.therap.2020.05.013_bib0300","first-page":"170","article-title":"L\u2019hypertension art\u00e9rielle en France\u00a0: pr\u00e9valence, traitement et contr\u00f4le en 2015 et \u00e9volutions depuis 2006","author":"Perrine","year":"2018","journal-title":"Bull Epidemiol Hebd"},{"issue":"10","key":"10.1016\/j.therap.2020.05.013_bib0305","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","volume":"36","author":"Williams","year":"2018","journal-title":"J Hypertens"},{"key":"10.1016\/j.therap.2020.05.013_bib0310","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1477-7525-4-35","article-title":"Quality of life in patients with psoriasis","volume":"4","author":"Bhosle","year":"2006","journal-title":"Health Qual Life Outcomes"},{"issue":"9","key":"10.1016\/j.therap.2020.05.013_bib0315","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/jamadermatol.2014.1019","article-title":"Psoriasis provoked or exacerbated by medications: identifying culprit drugs","volume":"150","author":"Armstrong","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.therap.2020.05.013_bib0320","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions: a systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf"},{"issue":"2","key":"10.1016\/j.therap.2020.05.013_bib0325","doi-asserted-by":"crossref","first-page":"94","DOI":"10.4103\/0378-6323.39688","article-title":"Psoriasiform dermatoses","volume":"74","author":"Sehgal","year":"2008","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"6","key":"10.1016\/j.therap.2020.05.013_bib0330","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1684\/ejd.2014.2452","article-title":"Calcium\u00a0\u2013\u00a0a central regulator of keratinocyte differentiation in health and disease","volume":"24","author":"Elsholz","year":"2014","journal-title":"Eur J Dermatol"},{"issue":"6","key":"10.1016\/j.therap.2020.05.013_bib0335","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0906-6705.2006.00430.x","article-title":"Expression of voltage-gated calcium channel subunit alpha1C in epidermal keratinocytes and effects of agonist and antagonists of the channel on skin barrier homeostasis","volume":"15","author":"Denda","year":"2006","journal-title":"Exp Dermatol"},{"issue":"12","key":"10.1016\/j.therap.2020.05.013_bib0340","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s40264-019-00865-8","article-title":"Psoriasis after exposure to angiotensin-converting enzyme inhibitors: French pharmacovigilance data and review of the literature","volume":"42","author":"Azzouz","year":"2019","journal-title":"Drug Saf"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595720301116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595720301116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:53:38Z","timestamp":1758567218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595720301116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0040595720301116"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2020.05.013","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Calcium channel blocker exposure and psoriasis risk: Pharmacovigilance investigation and literature data","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2020.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}